Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.08 AUD | -0.48% | -6.31% | +16.85% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 53.2 | 37.24 | 54.08 | 104.9 | 76.59 | 95.85 |
Enterprise Value (EV) 1 | 44.33 | 29.11 | 41.68 | 89.34 | 61.51 | 71.61 |
P/E ratio | 21.8 x | 11.7 x | 8.64 x | 12.2 x | 10.3 x | 10.7 x |
Yield | 3.87% | 5.6% | 4.25% | 3.03% | 4.43% | 5.06% |
Capitalization / Revenue | 1.29 x | 0.88 x | 1.16 x | 1.84 x | 1.15 x | 1.29 x |
EV / Revenue | 1.08 x | 0.69 x | 0.9 x | 1.56 x | 0.92 x | 0.97 x |
EV / EBITDA | 6.86 x | 6.65 x | 5.34 x | 7.95 x | 5.6 x | 5.92 x |
EV / FCF | 5.87 x | 13.9 x | 6.2 x | 19.2 x | 32.2 x | 6.41 x |
FCF Yield | 17% | 7.19% | 16.1% | 5.22% | 3.1% | 15.6% |
Price to Book | 2.38 x | 1.65 x | 2.19 x | 3.41 x | 2.09 x | 2.31 x |
Nbr of stocks (in thousands) | 54,842 | 55,587 | 54,083 | 55,188 | 56,527 | 53,850 |
Reference price 2 | 0.9700 | 0.6700 | 1.000 | 1.900 | 1.355 | 1.780 |
Announcement Date | 27/03/19 | 26/03/20 | 25/03/21 | 24/03/22 | 24/03/23 | 18/03/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 41.15 | 42.45 | 46.48 | 57.1 | 66.89 | 74.16 |
EBITDA 1 | 6.464 | 4.38 | 7.809 | 11.24 | 10.98 | 12.1 |
EBIT 1 | 6.076 | 4.107 | 7.569 | 11.02 | 10.73 | 11.87 |
Operating Margin | 14.77% | 9.67% | 16.28% | 19.29% | 16.04% | 16% |
Earnings before Tax (EBT) 1 | 4.33 | 4.428 | 8.158 | 11.2 | 10.74 | 12.45 |
Net income 1 | 2.439 | 3.136 | 6.094 | 8.292 | 7.084 | 9.08 |
Net margin | 5.93% | 7.39% | 13.11% | 14.52% | 10.59% | 12.24% |
EPS 2 | 0.0444 | 0.0573 | 0.1158 | 0.1561 | 0.1312 | 0.1660 |
Free Cash Flow 1 | 7.556 | 2.094 | 6.723 | 4.665 | 1.908 | 11.17 |
FCF margin | 18.36% | 4.93% | 14.46% | 8.17% | 2.85% | 15.06% |
FCF Conversion (EBITDA) | 116.89% | 47.8% | 86.1% | 41.49% | 17.38% | 92.35% |
FCF Conversion (Net income) | 309.79% | 66.76% | 110.33% | 56.26% | 26.94% | 123.01% |
Dividend per Share 2 | 0.0375 | 0.0375 | 0.0425 | 0.0575 | 0.0600 | 0.0900 |
Announcement Date | 27/03/19 | 26/03/20 | 25/03/21 | 24/03/22 | 24/03/23 | 18/03/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 8.87 | 8.13 | 12.4 | 15.5 | 15.1 | 24.2 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | 7.56 | 2.09 | 6.72 | 4.66 | 1.91 | 11.2 |
ROE (net income / shareholders' equity) | 10.3% | 13.8% | 25% | 30.1% | 21.9% | 22.7% |
ROA (Net income/ Total Assets) | 11.1% | 7.11% | 12.5% | 16.3% | 13.8% | 13.3% |
Assets 1 | 22.05 | 44.12 | 48.71 | 50.81 | 51.27 | 68.32 |
Book Value Per Share 2 | 0.4100 | 0.4100 | 0.4600 | 0.5600 | 0.6500 | 0.7700 |
Cash Flow per Share 2 | 0.2000 | 0.1900 | 0.2700 | 0.2900 | 0.2800 | 0.4400 |
Capex 1 | 0.37 | 0.05 | 0.09 | 0.16 | 0.14 | 0.66 |
Capex / Sales | 0.9% | 0.13% | 0.19% | 0.27% | 0.21% | 0.89% |
Announcement Date | 27/03/19 | 26/03/20 | 25/03/21 | 24/03/22 | 24/03/23 | 18/03/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+16.85% | 76.97M | |
+29.98% | 682B | |
+30.34% | 586B | |
-3.52% | 364B | |
+18.59% | 327B | |
+4.07% | 285B | |
+16.21% | 240B | |
+9.66% | 209B | |
-6.83% | 203B | |
+7.09% | 165B |
- Stock Market
- Equities
- VLS Stock
- Financials Vita Life Sciences Limited